Next Article in Journal
RTK Inhibitors in Melanoma: From Bench to Bedside
Previous Article in Journal
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
 
 
Review

Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies

Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Line Bjørge
Cancers 2021, 13(7), 1694; https://doi.org/10.3390/cancers13071694
Received: 16 March 2021 / Revised: 26 March 2021 / Accepted: 31 March 2021 / Published: 2 April 2021
(This article belongs to the Section Methods and Technologies Development)
Novel treatments in immunotherapy for gynecologic oncology have not successfully developed from preclinical research to clinical trials. Preclinical models used to investigate immunotherapy agents are summarized in order to enhance understanding of the inherent limitations and areas of improvement necessary to optimize this research. It is necessary to develop and utilize appropriate preclinical models whose outcomes can be translated to clinical practice in order to identify novel treatments to improve outcomes in patients with gynecologic malignancies.
Gynecologic malignancies are increasing in incidence, with a plateau in clinical outcomes necessitating novel treatment options. Immunotherapy and modulation of the tumor microenvironment are rapidly developing fields of interest in gynecologic oncology translational research; examples include the PD-1 (programmed cell death 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) axes and the Wnt pathway. However, clinical successes with these agents have been modest and lag behind immunotherapy successes in other malignancies. A thorough contextualization of preclinical models utilized in gynecologic oncology immunotherapy research is necessary in order to effectively and efficiently develop translational medicine. These include murine models, in vitro assays, and three-dimensional human-tissue-based systems. Here, we provide a comprehensive review of preclinical models for immunotherapy in gynecologic malignancies, including benefits and limitations of each, in order to inform study design and translational research models. Improved model design and implementation will optimize preclinical research efficiency and increase the translational value to positive findings, facilitating novel treatments that improve patient outcomes. View Full-Text
Keywords: gynecologic oncology; translational research; preclinical models; immunotherapy; cancer gynecologic oncology; translational research; preclinical models; immunotherapy; cancer
Show Figures

Graphical abstract

MDPI and ACS Style

Dholakia, J.; Scalise, C.; Arend, R.C. Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. Cancers 2021, 13, 1694. https://doi.org/10.3390/cancers13071694

AMA Style

Dholakia J, Scalise C, Arend RC. Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. Cancers. 2021; 13(7):1694. https://doi.org/10.3390/cancers13071694

Chicago/Turabian Style

Dholakia, Jhalak, Carly Scalise, and Rebecca C. Arend. 2021. "Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies" Cancers 13, no. 7: 1694. https://doi.org/10.3390/cancers13071694

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop